Nugliptin 50 Tablet contains Vildagliptin 50 mg, a potent oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is indicated for the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin, to improve glycemic control. Vildagliptin exerts its therapeutic effect by selectively inhibiting the DPP-4 enzyme, thereby prolonging the activity of incretin hormones like GLP-1 and GIP. This results in enhanced glucose-dependent insulin secretion and suppression of glucagon release, leading to improved postprandial and fasting blood glucose levels. Nugliptin 50 Tablet is generally well tolerated, with a low risk of hypoglycemia when used as monotherapy. It is recommended to be taken orally, once or twice daily, with or without food, as directed by a healthcare professional. Dose adjustments may be necessary in patients with renal impairment. Common adverse effects include headache, dizziness, and gastrointestinal disturbances. Regular monitoring of blood glucose and renal function is advised during therapy. Nugliptin 50 Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.